Uso da hidroxiuréia na anemia falciforme: uma revisão da literatura

Abstract

Hydroxyurea (HU) is the most important advance in the treatment of patients with sickle cell disease (SCD). Sickle cell disease is a debilitating and hereditary disease most common in Brazil and worldwide, with a predominance of black people. The aim of this study was to analyze the importance, benefits and adverse reactions of using hydroxyurea in the treatment of sickle cell anemia through a literature review. The research was conducted through bibliographic analysis by the literature review method performed in the Latin American and Caribbean Health Sciences Information System (LILACS), Scientific Electronic Library Online (SCIELO) databases. The following descriptors were used to survey the articles: Hydroxyurea, Sickle Cell Anemia, Sickle Cell Disease, articles published between 2006 and 2016 in Portuguese language were selected. Thus, 13 articles, through content analysis, were built four analytical categories: Characterization of sickle cell anemia, Benefits expected in the treatment with the use of UH, Criteria used for treatment with UH, Adverse reactions to UH. UH brings a quality of life for the patient as it reduces the number of hospitalizations and length of stay, decreases blood transfusions, reduces painful crises and occurrences of Acute Thoracic Syndrome (STA), minimizes splenic seizures and possible seizures. acute neurological events, generates regression or stabilization of organ damage, reducing the mortality of these patients by up to 40%.

Chronic osteo-articular changes in patients with sickle cell disease

“…A review article on the role of HU in SCD describes the importance of this medication in reducing the morbidity and mortality in these individuals [27]. Because of the effects of HU in reducing the sickling of red blood cells, elevating HbF, reducing oxidative stress and vasoocclusive crisis consequently, we infer that HU also has a positive impact on osteoarticular lesions, as reinforced by the findings of the present study.…”

Impact of temporary and involuntary suppression of hydroxyurea treatment on hematological and clinical parameters in patients with sickle cell disease

“…Typically, these crises are of excruciating course and sudden onset, but some patients experience a gradual episode of pain. Almost all affected individuals will present an acute pain crisis episode over their lifetime, often they happen with no Research, Society and Development, v. 13, n. 1, e3013144727, 2024 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v13i1.44727 prodromes and dampen the quality of life (Sousa et al, 2020).…”